|

As
We See
It... First
Quarter 2005
The first quarter
of 2005 was disappointing. While we enjoyed strong performances from some
stocks, we had weak returns from several others including our largest and most
successful long-term holding, Doral Financial. In Doral’s case the share price
has been cut by two thirds, contributing to our worst performance relative to
the S&P 500 since September of 1997. These episodes are infrequent, but
painful nonetheless.
Doral’s recent
underperformance was driven by an abrupt loss of confidence in the company by
Wall Street analysts and, subsequently, some large shareholders. Scrutiny is
focused on assumptions that management made when valuing financial assets on the
balance sheet, as required by regulators and accounting rule makers. Some felt
that these assumptions, which came to light when the company reported fourth
quarter earnings, were too aggressive and overstated the value of the assets in
question. Doral’s management has decided to switch to a more conservative
accounting treatment and business model, the first step in putting this issue
behind them.
We use Wall Street
research only peripherally, preferring instead to do our own primary research
and look to independent sources to validate or disprove our investment thesis.
As such, we can objectively assess the business itself. Is the franchise
damaged? No, we do not think so. We feel that the same dynamics that made Doral
an attractive investment years ago remain in place. Is management credible? We
believe so, but they do need to focus on running the business and capitalizing
on their market position.
Doral was not the
only detractor: Boston Scientific and Varian Medical were also weak in the
quarter. In both cases we remain comfortable with the long term prospects
despite the near term pressures on their stock prices. Finally, growth stocks
underperformed the market, and commodity plays, namely energy stocks out
performed. We are typically underweight undifferentiated cyclical companies.
We continue
to remain cautious on the outlook for the economy, but our approach remains
consistent. We search for companies that have sustainable competitive advantages
that will generate superior returns, and then are disciplined about investing in
them at attractive valuations. We look to hold them for the long term, but must
sometimes weather market volatility. This approach has served our clients well
over the long term, as they have handsomely out-performed the S&P over the
last three, five and ten year periods.
Notes From the Road by
Cassandra Hardman…
I recently
returned from a trip to the Far East, which began in Hong Kong. My first trip to
what is now a "special administrative region" of China was in the
mid-80’s, when the British influence was very evident. Today, there are
remnants of the colonial era, but to this visitor, Hong Kong has become
strikingly more "Chinese". In the ‘80’s, most of the analysts I
met with were British; on this trip all were Chinese. While the capitalist
feeling remains, Hong Kong’s renowned entrepreneurial spirit seemed less
evident; perhaps not so much diminished, as less maverick and more orderly.
Traveling on through China, signs
of the booming economy were abundant. Even in smaller cities, cranes could be
seen everywhere, building high-rise office and apartment towers. The contrasts
remained: street sweepers and groundskeepers in traditional bamboo hats, looking
much as they would have 50 years ago, while young women in tight designer jeans
and stilettos bicycled past them on their way home from office jobs; luxury cars
passing ox-drawn carts filled with vegetables. And everywhere, an overabundance
of workers, from restaurants to small shops, evidence of the potential for
productivity improvements over time.
From an
investment standpoint, I came away feeling encouraged, yet frustrated. There are
a good number of interesting listed companies, but share prices are still too
high. One example is China Life, China’s largest life insurer. With rising
affluence, demand for life insurance in China is in a secular growth phase, in
sharp contrast to much of the rest of the world. Unfortunately though, the
valuation of the stock is higher than that of many well-capitalized global
insurers. While China Life’s growth prospects might support a premium, the
risks of investing in a Chinese company, particularly one which is still
majority-owned by the government, are high enough that we would want to buy the
stock at a discount. We still need to be patient.

|